Fig. 6: T-DM1 and RAB5A correlation in a subset of patients in KAMILLA.
From: RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
A Box blot indicating the distribution of PFS in RAB5A low (Allred score 0–6, N = 11 independent samples) and RAB5A-high (Allred score 7 and 8, N = 8 independent samples) expressing patients. The midline represents the median of progression-free survival. The upper and lower limits of the box correspond to the 75% and 25% percentile of progression-free survival respectively; the whiskers represent the 90% and 10% percentile. The data points represent the individual data points in each group. A Mann–Whitney rank-sum test was used to determine the statistical difference in the median values between the two groups. B Exemplified images (×40 objective) of RAB5A IHC for Allred score 0 (patient #20), Allred score 3 (patient # 19), Allred score 6 (patient #21), Allred score 7 (patient #24) and Allred score 8 (patient #15). Scale bars: 100 µm. All samples were manually screened by 2 observers. Consensus on staining intensity and amount was obtained, and representative areas defined. Number of images captured from each slide: patient #20 4 images, patient #19 10 images, patient #21 8 images, patient #24 6 images, patient #15 4 images. Source data are provided as a Source Data file.
